Disclaimer

Access to the information and documents on this part of the website is restricted for regulato-ry reasons. You are requested to review the following information and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.

DISCLAIMER – IMPORTANT

Due to applicable legal restrictions, the information contained in this section of the website is restricted and is not for release, publication or distribution, directly or indirectly, in whole or in part, in or into the United States of America, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or any other jurisdiction in which such release, publication or distribution would be unlawful. We apologize for any inconvenience this may cause. Click here to return to the homepage.

Important information

The materials contained herein are not for general release, publication or distribution, directly or indirectly, in whole or in part, in or into Australia, Hong Kong, Canada, Ja-pan, New Zealand, Singapore, South Africa, the United States of America or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction. Access to the information and documents on this portion of the web-site is restricted for regulatory reasons. You are requested to review the following infor-mation and make the following confirmation each time you seek to access this restricted information. Your confirmation must be true and accurate.

 

The information contained in this section of the website of Oncopeptides AB (publ) (the “Company”) is (a) only intended for, and may only be accessed by, or distributed or dissem-inated, directly or indirectly, in whole or in part, to persons resident and physically present outside the United States of America (including its territories and possessions, any state of the United States and the District of Columbia, the “United States”), Australia, Hong Kong, Ja-pan, Canada, New Zealand, Singapore or South Africa, and resident and physically present in a jurisdiction where to do so will not constitute a violation of the local securities laws or regu-lations of such jurisdiction, and (b) does not constitute an offer to sell or the solicitation of an offer to buy or acquire any securities of the Company in the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or any other jurisdiction where to do so might constitute a violation of the local securities laws or regulations of such juris-diction.

 

The securities of the Company referred to in this section of the website (the “Securities”) have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”) or with any securities regulatory authority of any state of the United States for offer or sale as part of their distribution and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable securi-ties laws of any state or other jurisdiction of the United States. The Securities have not been and will not be registered under the applicable securities laws of Australia, Hong Kong, Ja-pan, Canada, New Zealand, Singapore, South Africa or any other jurisdiction in which it would be unlawful or would require registration or other measures, and therefore may not be offered or sold to or for the account or benefit of any person having a registered address in, or located or resident in, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa or any other jurisdiction in which it would be unlawful or would require regis-tration or other measures.

 

Access to the information contained on this portion of the website may be illegal in certain jurisdictions, and only certain categories of persons may be authorized to access such infor-mation and documents. All persons who wish to have access to the documents contained in this section of the Company’s website should first ensure that they are not subject to local laws or regulations that prohibit or restrict their right to access this section of the website, or require registration or approval for any acquisition of securities by them. No such registration or approval has been or will be obtained. The Company assumes no responsibility if there is a violation of applicable law and regulations by any person.

 

If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.

 

I therefore certify that:

 

  1. I am resident and physically present in a country outside the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Singapore and South Africa;
  2. I am authorized to access the information and documents contained on this portion of the website without being subject to any legal restriction and without any further ac-tion required by the Company;
  3. I will not transmit or otherwise send any information contained in this website to pub-lications with a general circulation in the United States; and
  4. I have read, understand and agree to comply with all of the restrictions set forth above.
I cannot confirm I confirm
March 13, 2024

Oncopeptides carries out rights issue

Oncopeptides AB recently announced that the Board of Directors has decided to carry out a fully guaranteed new share issue of approximately SEK 300 million with preferential rights for the company’s existing ordinary shareholders

To find out more, please look at the following information:

  • Click here to access the designated rights issue web page.
  • Click here to read the press release announcing the final outcome in the fully guaranteed rights issue, published on May 6, 2024
  • Click here to read the press release announcing that the prospectus relating to the rights issue is published on April 17, 2024.
  • Click here to read the press release announcing final terms for the fully guaranteed rights issue, published on March 8, 2024.
  • Click here to read the press release announcing the rights issue, published on March 13, 2024.
  • Click here to watch the investor conference following the rights issue announcement.
  • See Oncopeptalks and investor Q&A below.

Click here to read the press release published on Wednesday March 13, 2024.

Oncopeptalks

Listen to Sofia Heigis, CEO, and Henrik Bergentoft, CFO, talk about why Oncopeptides is carrying out a new share issue, where the money will go, what a rights issue really is and what you as a current or potential shareholder should think about.

Questions and answers for investors

What is this?

Oncopeptides has announced that it is carrying out a fully guaranteed rights issue of approximately SEK 300 million with the support of our major shareholders. We are doing it because we have a need for capital to get us to 2026, when we expect to be profitable.

What will the money be used for?

For those who have followed us recently, it is hopefully clear that our absolute focus is on commercialization in Europe, and that is also where the money will go.

In addition to that, we will also continue to drive the development of our pipeline forward, while we also continue to work to find markets outside Europe for Pepaxti, however, it is not something that drives particularly much costs as we work towards partnerships.

What does a rights issue entail?

A rights issue is a way for a company to raise more money and through selling more shares, with preferential rights to current shareholders. The idea is a bit like a “first dib” for those who have already invested in the company.

To make it fair, the chance of buying is based on how many shares you already own. For example, if you own 10% of the company, you’ll get the chance to buy 10% of the new shares first. This gives current owners a chance not to have their share diluted, i.e. their ownership does not decrease in percentage because there are more shares available after the issuance.

To ensure that the rights issue is successful, the issue price is set below the current share price. Existing shareholders will thus receive a “discount” on the newly issued shares. A shareholder can choose between either participating in the rights issue or selling the subscription rights. Otherwise, the “discount”, the difference between the share price and the issue price, is lost. If the shareholder chooses not to subscribe for the rights issue, the shareholding in the company is also reduced.

How does the issue affect my current ownership?

Provided that a shareholder chooses to subscribe for the issue, the ownership will remain with the same percentage as before of all the company’s shares.

What is the subscription price for new shares?

The final terms of the rights issue, including the subscription price and the number of newly issued shares, will be resolved by the Board of Directors no later than five business days prior to the record date for the rights issue and then be published in a prospectus. The prospectus is intended to be published on 17 April.

How is the subscription price determined?

The subscription price for a new share issue is determined through a combination of several factors, including the market’s valuation and demand from investors.

Why aren´t the terms immediately available?

The short answer is that we want to let the market have a hand in the pricing of the stock. This is a common arrangement where the exact price for participating in the rights issue is not set until closer to the extraordinary general meeting and when the subscription period is to begin. The reason for this is that we want the discount to be appropriately sized for the issue, and this can be assessed with greater certainty closer to the transaction being completed.

To ensure that the new share issue is successful, the issue price is typically set below the current share price, i.e. existing shareholders thereby receive a “discount” on the newly issued shares. A shareholder can choose between either participating in the rights issue or selling the subscription rights. Otherwise, the “discount”, the difference between the share price and the issue price, is lost. If the shareholder chooses not to subscribe for the rights issue, the shareholding in the company is also reduced.

Will it be possible to sell my subscription rights/to buy more subscription rights?

Yes – it will be possible to trade subscription rights on Nasdaq Stockholm between April 19 and April 29.

What happens if I don’t choose to sign up for my rights?

Existing shareholders should, if they do not choose to subscribe, sell their subscription rights before April 29, as the value of the rights will otherwise be lost.

How has the company’s management positioned itself in the rights issue? Will they attend?

The vast majority of the company’s management has undertaken to participate in the issue.

What is an ordinary stock? Do I have it?

Yes, all regular shareholders have what is commonly referred to as common stock.

What is a BTA?

In the context of a rights issue, BTA stands for “Paid Subscribed Share”. When an investor chooses to participate in a rights issue and subscribes for new shares, it may take some time before the new shares are registered with the Swedish Companies Registration Office and the investor is formally registered as the owner of the shares. During this period, between payment and registration, the investor receives BTAs as proof that the shares have been subscribed and paid for, but not yet registered.

BTAs gives the investor a right to receive the actual shares in the future. These paid and subscribed shares will be traded on the stock exchange between April 19 and May 13, giving investors the opportunity to buy or sell their BTAs before they are converted into ordinary shares, after the issue has been registered and the shares have been issued. This is done to provide liquidity and flexibility for those participating in the issue.

When will the prospectus be published?

A prospectus with the final terms of the rights issue, including the subscription price and the number of newly issued shares, will be published on April 17.

Where can I find more information and details about the rights issue?

Prior to any investment decisions, please refer first and foremost to the prospectus that will be approved and published in connection with the rights issue and be available on our website, under Investors. You can also contact the company’s Head of Investor Relations, David Augustsson.